Bristol-Myers Squibb Company (BMY:NYSE) closed at $59.75 on October 16, 2026, down 1.35% on the day. The stock trades 13.0% below its 52-week high of $68.64 and 40.5% above its 52-week low of $42.52. Over the past year, it gained 36.9%. Bristol-Myers Squibb Company is part of the Health Care sector (Major Pharmaceuticals).
| 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|
| +3.77% | -4.92% | -0.68% | +1.05% | +36.95% |
In 252 trading sessions since October 16, 2025, BMY closed higher on 125 days (50%). Its best day was October 30, 2025 (+7.09%) and its worst was November 14, 2025 (-4.07%). It never moved 10% or more in a single session.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers chemically-synthesized drug and biologic in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology comprising human immunodeficiency virus infection (HIV). Its products include Empliciti, a humanized monoclonal antibody to treat multiple myeloma; Opdivo, a human monoclonal antibody to treat renal cell carcinoma, non-small cell lung cancer, classical Hodgkin lymphoma, gastric cancer, melanoma, metastatic urothelial carcinoma, and squamous cell carcinoma of the head and neck; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; and Yervoy, a monoclonal antibody for metastatic melanoma. The company's products also comprise Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation; Baraclude to treat chronic hepatitis B virus; Daklinza and Sunvepra to treat hepatitis C virus (HCV); Reyataz and Sustiva to tre...
Find more stocks like BMY with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.